Protara Therapeutics is trading 9.1% down at $3.60 after closing at $3.96 on August 19, 2026; no credible company-specific announcement dated August 20 was identified.
- The latest reported catalyst was Protara’s August 11 second-quarter update, which included a $21.7 million net loss and clinical-development updates, but it predates this move.
- Biotech is stronger pre-market, making sector strength an unlikely explanation.